New GERD Treatment Approved for Patients With Swallowing Difficulty

New formulations melts in patient's mouth
New formulations melts in patient's mouth

Takeda announced that the Food and Drug Administration (FDA) has approved Dexilant SoluTab (dexlansoprazole) delayed-release orally disintegrating tabs, a new formulation that melts in the patient's mouth. 

Dexilant SoluTab is a proton pump inhibitor (PPI) that is indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) and the maintenance of healed erosive esophagitis (EE) and relief of heartburn in patients aged ≥18 years.

RELATED: GERD Risks Jumps in Women Post-IVF - But Why?

Dexilant SoluTab consists of dual delayed release (DDR) technology that provides 2 releases of medication. It suppresses gastric acid secretion by specific inhibition of the (H+ , K+ )-ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid pump within the parietal cell, dexlansoprazole has been characterized as a gastric proton-pump inhibitor, in that it blocks the final step of acid production.

Dexilant is already available as 30mg and 60mg strength delayed-release capsules in 30-, 90-, and 1000-count bottles. Dexilant SoluTab will be available as 30mg strength delayed-release orally disintegrating tablets in 100-count unit dose packs. 

For more information call (877) 825-3327 or visit